Novartis gets EU approval for Cushing's drug
ZURICH (Reuters) - Swiss drug maker Novartis AG (NOVN.VX) said on Wednesday it has won European Union approval for its Signifor as the first medical therapy for Cushing's disease, a rare hormonal disorder.
Signifor, which is designed for Cushing's disease patients who cannot have surgery or for whom surgery has not been successful, had already won a green light from the European Medicines Agency (EMA) in January.
Cushing's is caused by a small tumour of the pituitary gland making too much of a hormone. Standard treatment is surgical removal of the tumour, but this does not always work.
- Tweet this
- Share this
- Digg this
- South Korea recovers first bodies from inside sunken ferry |
- Surrender talks set with separatists in Ukraine as standoff lasts into Easter |
- Special Report - How the U.S. made its Putin problem worse
- Malaysian plane search in 44th day, sea bed scans could end in days
- Prosecutors extend Korea ferry captain's detention as death toll mounts |